Generation Bio Co. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
| |||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 6, 2024, Generation Bio Co. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). A total of 66,489,181 shares of common stock were entitled to vote as of April 10, 2024, the record date for the Annual Meeting. There were 53,570,875 shares of common stock present virtually or represented by proxy at the Annual Meeting, constituting a quorum to conduct business.
The following proposals were voted upon at the Annual Meeting:
Proposal 1 | Election of Jeffrey Jonas, M.D., Geoff McDonough, M.D., and Donald Nicholson, Ph.D., as Class I directors to the Company’s board of directors, each to serve until the 2027 annual meeting of stockholders; |
Proposal 2 | Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; |
Proposal 3 | Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. |
On June 6, 2024, Broadridge Financial Solutions, Inc., the independent inspector of election for the Annual Meeting, delivered its final report as to the voting results for each of these proposals. The following are the final voting results for each of the items voted on at the Annual Meeting:
Proposal 1. Election of Class I Directors.
Nominee | Votes For | Votes Withheld | Broker | |||
Jeffrey Jonas, M.D. | 35,807,200 | 12,353,347 | 5,410,328 | |||
Geoff McDonough, M.D. | 47,658,822 | 501,725 | 5,410,328 | |||
Donald Nicholson, Ph.D. | 47,589,073 | 571,474 | 5,410,328 |
Based on the votes set forth above, the stockholders of the Company elected Jeffrey Jonas, M.D., Geoff McDonough, M.D., and Donald Nicholson, Ph.D., as Class I directors to the Company’s board of directors, each to serve until the 2027 annual meeting of stockholders.
Proposal No. 2. Ratification of Appointment of Ernst & Young LLP.
Votes For | Votes Against | Abstentions | |||
53,562,165 | 1,795 | 6,915 |
Based on the votes set forth above, the stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm to serve for the year ending December 31, 2024.
Proposal No. 3. Advisory (Non-Binding) Vote on Executive Compensation
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
47,772,176 | 373,246 | 15,125 | 5,410,328 |
Based on the votes set forth above, the stockholders of the Company approved, on an advisory (non-binding) basis, of the compensation of its named executive officers.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GENERATION BIO CO. | ||
Date: June 7, 2024 | By: | /s/ Geoff McDonough |
Name: Geoff McDonough, M.D. | ||
Title: President and Chief Executive Officer | ||